Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes ; - Company Begins DEFEND-2 While DEFEND-1 Study Continues Toward Completion -
Motivated families can make fitness a goal for all
Study: Cardiovascular Disease Risk Improves with Healthy Diet and Phytonutrient-Based Medical Food
Neogenix Oncology files patent application for cancer antigen
